InsidersTradesSigma
Track the Alzamend Neuro, Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Alzamend Neuro, Inc. has recorded 142 public disclosures. Market capitalisation: €7m. The latest transaction was disclosed on 31 August 2026 (Cession). Among the most active insiders: AULT MILTON C III. Every trade is accessible without an account.
142
Insider Decl.
n/a
Thresholds
€6m
94 ops.
Buy Volume
€652,165
16 ops.
Sell Volume
34Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 31 August 2026
Declarations142 total
2,000 shares@ US$1.5581Common StockSEC:0001214659-26-011121:0
108,388 shares@ US$1.0047Common StockSEC:0001214659-26-011110:0
Canonical exit: 13 Jul 2026 (T+90)
2,000 shares@ US$1.0338Common StockSEC:0001214659-26-011110:1
Canonical exit: 13 Jul 2026 (T+90)
108,388 shares@ US$1.0047Common StockSEC:0001214659-26-011111:0
Canonical exit: 13 Jul 2026 (T+90)
2,000 shares@ US$1.0338Common StockSEC:0001214659-26-011111:1
Canonical exit: 13 Jul 2026 (T+90)
108,388 shares@ US$1.00471.54% mcap0.4% of flowCommon StockSEC:0001214659-26-004742:0
Canonical exit: 13 Jul 2026 (T+90)
1,851 shares@ US$2.06650.0% of flowCommon StockSEC:0001214659-25-018631:0
3,333 shares@ US$2.117835.1% of flowCommon StockSEC:0001214659-25-018437:0
30 shares@ US$2.290.1% of flowCommon StockSEC:0001214659-25-015288:0
61,743 shares@ US$2.322.4% of flowCommon StockSEC:0001214659-25-014861:0
100,000 shares@ US$2.323.9% of flowCommon StockSEC:0001214659-25-014752:0
100,000 shares@ US$2.323.9% of flowCommon StockSEC:0001214659-25-014629:0
37,738 shares@ US$2.31450.3% of flowCommon StockSEC:0001214659-25-014420:0
38,324 shares@ US$2.3090.3% of flowCommon StockSEC:0001214659-25-014420:1
3,566 shares@ US$2.33340.0% of flowCommon StockSEC:0001214659-25-014420:2
43,238 shares@ US$2.37571.9% of flowCommon StockSEC:0001214659-25-014210:0
77,009 shares@ US$2.34850.6% of flowCommon StockSEC:0001214659-25-014056:0
100,000 shares@ US$2.320.8% of flowCommon StockSEC:0001214659-25-014056:1
100,000 shares@ US$2.324.3% of flowCommon StockSEC:0001214659-25-013976:0
100,000 shares@ US$2.324.6% of flowCommon StockSEC:0001214659-25-011356:0
36,532 shares@ US$2.89760.4% of flowCommon StockSEC:0001214659-25-011043:0
8,311 shares@ US$2.68490.1% of flowCommon StockSEC:0001214659-25-011043:1
143,429 shares@ US$2.326.8% of flowCommon StockSEC:0001214659-25-010933:0
1,213 shares@ US$5.06040.0% of flowCommon StockSEC:0001214659-25-007625:0
3,334 shares@ US$0.985417.8% of flowCommon StockSEC:0001214659-25-004857:0
Canonical exit: 24 Jun 2025 (T+90)
25 of 142 declarations
关于 Alzamend Neuro, Inc.
Alzamend Neuro, Inc.（股票代码：ALZN）是一家总部位于美国的临床阶段生物制药公司，在美国纳斯达克上市。对于法语投资者而言，这是一家市值非常小的医疗保健公司，其投资案例主要由临床执行、监管进展和融资能力而非商业销售驱动。该公司成立于 2016 年，总部位于佐治亚州亚特兰大，与佛罗里达州有历史渊源，并与美国主要研究机构持续合作。([sec.gov](https://www.sec.gov/Archives/edgar/data/1677077/000121465925010763/u7925110k.htm?utm_source=openai)) Alzamend 的战略重点明确地放在神经退行性疾病和精神疾病上，特别是阿尔茨海默病、双相情感障碍、重度抑郁症和创伤后应激障碍。其目前的研发管线集中在两个主要项目上。AL001 是一种获得专利的离子共晶锂制剂，结合了锂、水杨酸盐和 L-脯氨酸，旨在改善锂向大脑的输送，同时与传统碳酸锂相比减少全身暴露。ALZN002 是一种基于细胞的治疗性疫苗方法，使用突变肽致敏细胞，旨在帮助恢复患者的免疫反应并清除大脑中的 β-淀粉样蛋白。这两种候选药物均根据需支付特许权使用费的全球独家许可从南佛罗里达大学研究基金会获得许可。([ir.alzamend.com](https://ir.alzamend.com/news-events/press-releases/detail/97/alzamend-neuro-announces-completion-of-clinical-portion-of?utm_source=openai)) 从竞争角度来看，Alzamend 在中枢神经系统药物开发中占据了一个高度专业化和投机的利基市场：下一代锂输送和阿尔茨海默病免疫疗法概念。该公司尚未有上市产品，因此投资论点取决于临床结果、监管里程碑以及其长期资助开发的能力。这使得该故事具有高风险/高回报的特点，伴随着早期生物技术发行人典型的重大稀释和执行风险。([ir.alzamend.com](https://ir.alzamend.com/company-information?utm_source=openai)) 最近的进展对股票叙事至关重要。在 2025 年和 2026 年，Alzamend 报告了 AL001 的多项 II 期更新，包括临床工作的启动和完成，最值得注意的是，初步阳性数据显示，与标准碳酸锂相比，在所有测量的大脑区域，生物等效性且大脑输送量在数值上更优。该公司还宣布，已于 2024 年 10 月恢复符合纳斯达克上市标准。这些里程碑改善了临床概况，但并未消除与开发阶段生物技术公司相关的固有二元风险。([ir.alzamend.com](https://ir.alzamend.com/news-events/press-releases/detail/93/alzamend-neuro-announces-dosing-of-first-patient-in-its?utm_source=openai))
